CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma

International Immunopharmacology

Volumn 34, Issue , 2016, Pages 101-106

  Han, Qinglin ^a   Shi, Hongguang ^a   Liu, Fan ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Macrophage; Osteosarcoma; PD 1; TIM 3

Indexed keywords

CD163 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 2; CELL SURFACE RECEPTOR; CYTOKINE; DIFFERENTIATION ANTIGEN; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CANCER INHIBITION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; YOUNG ADULT; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; IMMUNOLOGY; MACROPHAGE; METABOLISM; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TUMOR ESCAPE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; OSTEOSARCOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84959517116     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.01.023     Document Type: Article

References (26)

1. C.-H. Pui, A.J. Gajjar, J.R. Kane, I. a Qaddoumi, and A.S. Pappo Challenging issues in pediatric oncology Nat. Rev. Clin. Oncol. 8 2011 540 549 10.1038/nrclinonc.2011.95
2. N.C. Daw, C. a Billups, C. Rodriguez-Galindo, M.B. McCarville, B.N. Rao, A.M. Cain, and et al. Metastatic osteosarcoma Cancer 106 2006 403 412 10.1002/cncr.21626
3. N. Jaffe Osteosarcoma: Review of the past, impact on the future. The American experience Cancer Treat. Res. 152 2009 239 262 10.1007/978-1-4419-0284-9-12
4. C.A.S. Arndt, P.S. Rose, A.L. Folpe, and N.N. Laack Common musculoskeletal tumors of childhood and adolescence Mayo Clin. Proc. 87 2012 475 487 10.1016/j.mayocp.2012.01.015
5. J.C.M. Clark, C.R. Dass, and P.F.M. Choong A review of clinical and molecular prognostic factors in osteosarcoma J. Cancer Res. Clin. Oncol. 134 2008 281 297 10.1007/s00432-007-0330-x
6. C. DeRenzo, and S. Gottschalk Genetically modified T-cell therapy for osteosarcoma Adv. Exp. Med. Biol. 804 2014 323 340 10.1007/978-3-319-04843-7-18
7. N. Ahmed, V.S. Salsman, E. Yvon, C.U. Louis, L. Perlaky, W.S. Wels, and et al. Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression Mol. Ther. 17 2009 1779 1787 10.1038/mt.2009.133
8. Z. Li Potential of human γδ T cells for immunotherapy of osteosarcoma Mol. Biol. Rep. 40 2013 427 437 10.1007/s11033-012-2077-y
9. M. Kansara, M.W. Teng, M.J. Smyth, and D.M. Thomas Translational biology of osteosarcoma Nat. Rev. Cancer 14 2014 722 735 10.1038/nrc3838
10. D.M. Lussier, L. O'Neill, L.M. Nieves, M.S. McAfee, S.A. Holechek, A.W. Collins, and et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions J. Immunother. 38 2015 96 106 10.1097/CJI.0000000000000065
11. Y. Shang, Z. Li, H. Li, H. Xia, and Z. Lin TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers Oncol. Lett. 6 2013 490 494 10.3892/ol.2013.1410
12. E.P. Buddingh, M.L. Kuijjer, R. a J. Duim, H. Bürger, K. Agelopoulos, O. Myklebost, and et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents Clin. Cancer Res. 17 2011 2110 2119 10.1158/1078-0432.CCR-10-2047
13. L.C. Marais, and N. Ferreira Osteosarcoma in adult patients living with HIV/AIDS ISRN Oncol. 2013 2013 219369 10.1155/2013/219369
14. L. Monney, C. a Sabatos, J.L. Gaglia, A. Ryu, H. Waldner, T. Chernova, and et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease Nature 415 2002 536 541 10.1038/415536a
15. K. Sakuishi, L. Apetoh, J.M. Sullivan, B.R. Blazar, V.K. Kuchroo, and A.C. Anderson Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J. Exp. Med. 207 2010 2187 2194 10.1084/jem.20100643
16. D.L. Barber, E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, and et al. Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 2006 682 687
17. L.M. Francisco, P.T. Sage, and A.H. Sharpe The PD-1 pathway in tolerance and autoimmunity Immunol. Rev. 236 2010 219 242 10.1111/j.1600-065X.2010.00923.x
18. L. Golden-Mason, B.E. Palmer, N. Kassam, L. Townshend-Bulson, S. Livingston, B.J. McMahon, and et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4 + and CD8 + T cells J. Virol. 83 2009 9122 9130 10.1128/JVI.00639-09
19. J.P. Moorman, J.M. Wang, Y. Zhang, X.J. Ji, C.J. Ma, X.Y. Wu, and et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection J. Immunol. 189 2012 755 766 10.4049/jimmunol.1200162
20. R.B. Jones, L.C. Ndhlovu, J.D. Barbour, P.M. Sheth, A.R. Jha, B.R. Long, and et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection J. Exp. Med. 205 2008 2763 2779 10.1084/jem.20081398
21. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol. 23 2002 549 555 10.1016/S1471-4906(02)02302-5
22. F.A.W. Verreck, T. de Boer, D.M.L. Langenberg, L. van der Zanden, and T.H.M. Ottenhoff Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma-and CD40L-mediated costimulation J. Leukoc. Biol. 79 2006 285 293 10.1189/jlb.0105015
23. M.R. Smith Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance Oncogene 22 2003 7359 7368 10.1038/sj.onc.1206939
24. F. Wei, S. Zhong, Z. Ma, H. Kong, A. Medvec, R. Ahmed, and et al. Strength of PD-1 signaling differentially affects T-cell effector functions Proc. Natl. Acad. Sci. 110 2013 E2480 E2489 10.1073/pnas.1305394110
25. S. Theóleyre, K. Mori, B. Cherrier, N. Passuti, F. Gouin, F. Rédini, and et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: Use as a possible therapeutic approach of osteosarcoma BMC Cancer 5 2005 123 10.1186/1471-2407-5-123
26. P. Italiani, and D. Boraschi From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation Front. Immunol. 5 2014 514 10.3389/fimmu.2014.00514